Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas RNA-guided endonucleases hold great promise for disrupting or correcting genomic sequences through site-specific DNA cleavage and repair. However, the lack of methods for cell- and tissue-selective delivery currently limits both research and clinical uses of these enzymes. We report the design and in vitro evaluation of S. pyogenes Cas9 proteins harboring asialoglycoprotein receptor ligands (ASGPrL). In particular, we demonstrate that the resulting ribonucleoproteins (Cas9-ASGPrL RNP) can be engineered to be preferentially internalized into cells expressing the corresponding receptor on their surface. Uptake of such fluorescently labeled proteins in liver-derived cell lines HEPG2 (ASGPr+) and SKHEP (control; diminished ASGPr) was studied by live cell imaging and demonstrates increased accumulation of Cas9-ASGPrL RNP in HEPG2 cells as a result of effective ASGPr-mediated endocytosis. When uptake occurred in the presence of a peptide with endosomolytic properties, we observed receptor-facilitated and cell-type specific gene editing that did not rely on electroporation or the use of transfection reagents. Overall, these in vitro results validate the receptor-mediated delivery of genome-editing enzymes as an approach for cell-selective gene editing and provide a framework for future potential applications to hepatoselective gene editing in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This delivery mode can reduce possible off-target mutations relative to delivering Cas9-encoding DNA or mRNA due to the short half-life of RNPs 76,85-87 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
Self-citationGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
Self-citationGene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H. (2014) · Genome Research · doi:10.1101/gr.171264.113 · Cited by 655
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications
D'Souza, A. A., & Devarajan, P. V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.022 · Cited by 621
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Self-citationPermanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522
The asialoglycoprotein receptor: relationships between structure, function, and expression
Stockert, R. J. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.591 · Cited by 520
Lee, Y. C., Townsend, R. R., Hardy, M. R., Lönngren, J., Arnarp, J., Haraldsson, M., & Lönn, H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33240-x · Cited by 503
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
Self-citationLieber, A., He, C. Y., Meuse, L., Schowalter, D., Kirillova, I., Winther, B., & Kay, M. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8798-8807.1997 · Cited by 412
Traxler, E. A., Yao, Y., Wang, Y.-D., Woodard, K. J., Kurita, R., Nakamura, Y., Hughes, J. R., Hardison, R. C., Blobel, G. A., Li, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4170 · Cited by 366
Staahl, B. T., Benekareddy, M., Coulon-Bainier, C., Banfal, A. A., Floor, S. N., Sabo, J. K., Urnes, C., Munares, G. A., Ghosh, A., & Doudna, J. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3806 · Cited by 355
Self-citationMethods for Optimizing CRISPR-Cas9 Genome Editing Specificity
Tycko, J., Myer, V. E., & Hsu, P. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.07.004 · Cited by 305
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295
The Genotype-Tissue Expression (GTEx) project
Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2653 · Cited by 263
New Basic Membrane-Destabilizing Peptides for Plasmid-Based Gene Delivery in Vitro and in Vivo
Rittner, K., Benavente, A., Bompard-Sorlet, A., Heitz, F., Divita, G., Brasseur, R., & Jacobs, E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0523 · Cited by 257
Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
Oakes, B. L., Nadler, D. C., Flamholz, A., Fellmann, C., Staahl, B. T., Doudna, J. A., & Savage, D. F. (2016) · Nature Biotechnology · doi:10.1038/nbt.3528 · Cited by 200
Self-citationEndosomal Escape: A Bottleneck in Intracellular Delivery
Shete, H. K., Prabhu, R. H., & Patravale, V. B. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2014.9082 · Cited by 194
Rajeev, K. G., Nair, J. K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J. L. S., Yucius, K., Nguyen, T., Shulga‐Morskaya, S., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500023 · Cited by 185
Appelbaum, J. S., LaRochelle, J. R., Smith, B. A., Balkin, D. M., Holub, J. M., & Schepartz, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.022 · Cited by 170
Tanowitz, M., Hettrick, L., Revenko, A., Kinberger, G. A., Prakash, T. P., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx960 · Cited by 157
Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B., & Ernst, B. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.017 · Cited by 147
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Dai, W.-J., Zhu, L.-Y., Yan, Z.-Y., Xu, Y., Wang, Q.-L., & Lu, X.-J. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.58 · Cited by 144
Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells
Liu, J., Gaj, T., Yang, Y., Wang, N., Shui, S., Kim, S., Kanchiswamy, C. N., Kim, J., & Barbas, C. F. (2015) · Nature Protocols · doi:10.1038/nprot.2015.117 · Cited by 135
Molecular Regulation of Endocytosis
(2012) · InTech eBooks · doi:10.5772/2989 · Cited by 134
Li, Y., Huang, G., Diakur, J. M., & Wiebe, L. I. (2008) · Current Drug Delivery · doi:10.2174/156720108785915069 · Cited by 125
Long-Term Culture and Coculture of Primary Rat and Human Hepatocytes
Shulman, M., & Nahmias, Y. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-125-7_17 · Cited by 117
Sanhueza, C., Baksh, M. M., Thuma, B. A., Roy, M. D., Dutta, S., Préville, C., Chrunyk, B. A., Beaumont, K. C., Dullea, R., Ammirati, M. J., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12964 · Cited by 109
Self-citationDisposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Yu, R. Z., Graham, M. J., Post, N., Riney, S., Zanardi, T., Hall, S., Burkey, J., Shemesh, C. S., Prakash, T. P., Seth, P. P., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.26 · Cited by 96
Improved Cell-Penetrating Zinc-Finger Nuclease Proteins for Precision Genome Engineering
Liu, J., Gaj, T., Wallen, M. C., & Barbas, C. F. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.6 · Cited by 61
Receptor-mediated delivery of engineered nucleases for genome modification
Chen, Z., Jaafar, L., Agyekum, D. G., Xiao, H., Wade, M. F., Kumaran, R., Spector, D. L., Bao, G., Porteus, M. H., Dynan, W. S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt710 · Cited by 38
Cited by
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Self-citationCRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
“Another challenge is preventing uptake and editing in off-target cells; this could be addressed by utilizing a targeting molecule, such as a single-chain variable fragment or glycoprotein, through conjugation to the CRISPR RNP (168).”
BackgroundInfluentialSelf-citationStrategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430
Liu, C., Wan, T., Wang, H., Zhang, S., Ping, Y., & Cheng, Y. (2019) · Science Advances · doi:10.1126/sciadv.aaw8922 · Cited by 396
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Metadata
- Authors
- Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., Compte Barrón, J., McLellan, T. J., Bellenger, J., Feng, X., Varghese, A., Chrunyk, B. A., Borzilleri, K., Hesp, K. D., Zhou, K., Ma, N., Tu, M., Dullea, R., McClure, K. F., Wilson, R. C., Liras, S., Mascitti, V., & Doudna, J. A.
- Affiliations
- QB3 (US)
- Pfizer (United States) (US)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Liras, Spiros
- Mascitti, Vincent
- Doudna, Jennifer A.
- ORCID
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-04-18
- Volume
- 140
- Issue
- 21
- Pages
- 6596-6603
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC6002863
- OpenAlex
- W2801459452
- Cited by
- 163
- References
- 48
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 21 · 2020: 24 · 2019: 26 · 2018: 12
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Health and Medical Research Council (APP1090875)
- Pfizer (86059)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, asialoglycoprotein receptor, receptor-mediated delivery, ribonucleoprotein, endocytosis, hepatocytes, genome editing
- MeSH terms
- Gene Editing, Endonucleases, Humans, Protein Engineering, Molecular Structure, Cell Line, Tumor, Hep G2 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.